Backgrounds/Aims: Standard pancreatic resections are the current approach for patients with resectable, isolated pancreatic metastases of other neoplasms. However, the role of parenchyma-sparing pancreatectomies for such pathology is poorly investigated. The aim of the present study is to assess the oncological safety of central pancreatectomies for pancreatic metastases of other neoplasms. Methods: A literature search was performed in order to identify patients with central pancreatectomies for pancreatic metastases of other neoplasms. The available data of the patients were extracted and analyzed. Results: A total number of 16 patients were identified. Renal carcinoma was the primary origin for the largest number of these patients (11 patients -69%). The mean overall survival time was 109 months, with 1-, 5-and 10-year survival rates of 100%, 84%, and 60%, respectively. Conclusions: Although not often performed, a central pancreatectomy appears to be an oncologically safe surgical procedure in select patients with pancreatic metastases of other neoplasms of the pancreatic body and isthmus. However, no definitive conclusions should be drawn, based on the data provided in the present study, due to the limited number and heterogeneity of the patients. 
INTRODUCTION
A central pancreatectomy is a conservative surgical procedure that preserves the spleen and pancreatic parenchyma. It was proposed as alternative to distal/extended distal pancreatectomies. 1, 2 The advantage of a central pancreatectomy is better preservation of both endocrine and exocrine pancreatic function, compared with a distal pancreatectomy, 2 an extended distal pancreatectomy, 3 and a spleen-preserving distal pancreatectomy. 4 The major drawbacks of a central pancreatectomy are high morbidity and non-nil mortality rates, 1, 5, 6 particularly in aged and obese patients with diabetes. 7 Pancreatic fistulae represent the main source of morbidity after a central pancreatectomy, being reported in up to 63% of the patients. 1 The majority of the reported central pancreatectomies worldwide were performed for a benign/low-grade malignant tumor of the mid-portion of the pancreas. 1,2 Thus, cystadenomas and pancreatic neuroendocrine tumors were the main indications for a central pancreatectomy.
1,2
However, the role of a central pancreatectomy for pancreatic malignancies, such as pancreatic metastases of other neoplasms, is poorly investigated.
The aim of the present study is to assess the oncological safety of central pancreatectomies for pancreatic metastases of other neoplasms, based on data reported in the literature.
MATERIALS AND METHODS

Patients
Patients were extracted from articles identified by electronic searching in PubMed-Medline and Google Scholar and by reviewing the references of the identified articles.
The searched words were "central pancreatectomy", "medial pancreatectomy", "median pancreatectomy", "meso-pancreatectomy", "middle pancreatectomy", "segmental resection of the pancreas", "middle segmental resection of the 
RESULTS
A total number of 16 patients with central pancreatectomies for pancreatic metastases of other neoplasms were identified worldwide, 3, 6, [8] [9] [10] [11] [12] [13] [14] [15] [16] as shown in Table 1 . Renal carcinoma was the primary origin for the largest number of patients (11 patients -69%). The mean overall survival time of the patients was 109 months, with 1-, 5-and 10-year survival rates of 100%, 84%, and 60%, respectively ( Fig. 1) . After standard pancreatic resections for isolated pancreatic metastases of other neoplasms the reported median/mean survival time varied between 19 to 119 months, with 5-year survival rates between 36.2% and 88%. [17] [18] [19] [20] [21] 23 These results are comparable with those reported in the present study. Consequently, a central pancreatectomy appears to have similar oncological outcomes to standard pancreatic resections.
DISCUSSION
Pancreatic metastases of other neoplasms are widely considered to be a part of a systemic oncological disease. 18 These patients are likely to receive chemotherapy.
Chemotherapy in a patient with diabetes can be challenging because some chemotherapeutic agents can lead to or exacerbate potential renal, cardiac or neuropathic complications complications. 28 Thus, sparing the pancreatic parenchyma represents an important issue in these patients and has the potential to mitigate the complications of chemotherapy by reducing the risk of postoperative diabetes. 21, 24 It is widely accepted that a central pancreatectomy, of all of the pancreatic resections, has the lowest potential of developing postoperative diabetes. The results of this study should be regarded with caution because there are important limitations. The study includes a small number of patients, coming from many surgical centers, with different approaches and criteria selection, for a parenchyma-sparing surgical procedure. 
